For too long, the behavioral health industry has lacked the accountability mechanisms required to deliver on the high quality care that patients deserve. Provider organizations are proving day in, day out that when strong accountability becomes the standard, patients benefit, and the system as a whole grows stronger. The post It’s Time for Health Plans…
Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million. Meanwhile, Pfizer continued the culling of its gene therapies with the discontinuation of Beqvez for hemophilia B. The post Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity appeared first on MedCity News.
Hospitals are adopting AI technology more than ever before, but they still face challenges when it comes to measuring the impact of these solutions and scaling them, noted Kiran Mysore, chief data & analytics officer at Sutter Health. The post Hospitals Are Adopting AI — But Can They Measure and Scale These Tools? appeared first…
Future Family launched a nationwide IVF insurance product on Wednesday. If families don’t achieve a live birth after two cycles of IVF, they can get their money back. The post Future Family Guarantees ‘Baby or Your Money Back’ with New Nationwide IVF Insurance appeared first on MedCity News.
The conversations in Nashville reinforced the idea that while innovation remains essential, vendors must navigate the fine balance between bold ideas and real-world implementation, demonstrating not just promise but tangible outcomes. The post ViVE 2025: The Crossroads of Digital Health Innovation and Realities appeared first on MedCity News.
Blood centers are neutral partners, as they do not compete with hospitals for patients. Instead, they complement hospitals by providing a focused array of high-quality, specialized, patient-centric services, allowing hospitals to maintain primary relationships with patients and their families. The post Blood Centers Complement Hospitals to Drive Cell and Gene Therapy Access appeared first on…
This year’s ViVE conference was full of announcements — from acquisitions to rebrands to product launches. This list compiles short summaries for seven of the conference’s most notable announcements. The post 7 ViVE Announcements You Don’t Want to Miss appeared first on MedCity News.
Millie’s Series A round was co-led by TMV and Foreground Capital. The financing will help the company expand its offerings and footprint. The post Millie Raises $12M to Advance Maternal Healthcare appeared first on MedCity News.
FibroGen secured regulatory approvals for roxadustat in China and Europe, but the FDA rejected the drug and asked for another clinical trial. By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially resuming development of roxadustat in another indication. The post AstraZeneca Secures China Rights to Anemia…
Improving the identification and validation of disease-specific drug targets in a cell-type and patient-specific manner early on will not only reduce the failure rate and cost that is so inherent in current drug development processes but also allow the development of more effective precision medicines, improving patient outcomes. The post The Future of Drug Discovery…